alexa Cerebral Hemorrhage In Haemodialysis Patients
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference on Nephrology & Therapeutics
June 26-27, 2014 Valencia Conference Centre, Valencia, Spain

Mabel Aoun
ScientificTracks Abstracts: J Nephrol Ther
DOI: 10.4172/2161-0959.S1.013
A ntiplatelets therapy and anticoagulants are widely used in hemodialysis (HD) patients as a primary or secondary prevention for cardiovascular diseases. Their major side effect in this population is cerebral or digestive hemorrhage. We conducted a retrospective study in our center between 2005 and 2011 to find out whether the prescription of these drugs is well indicated and when it should be avoided in hemodialysis patients. 125 patients were dialyzed in our center between January 2005 and December 2011. They were divided into two groups. Group I included 68 patients who were not taking any antiplatelet or anticoagulant treatment. Group II included 57 patients: 26 were taking aspirin, 16 clopidogrel and 15 acenocoumarol. The mortality in Group I was 50% without any hemorrhagic complications. In Group 2 the mortality was 74 %. 19% in group 2 experienced hemorrhagic complications (6 cerebral and 5 digestive). 9 out of 42 deaths (21%) in Group 2 were secondary to hemorrhagic events: five patients on antiplatelet therapy developed hemorrhagic stroke and four patients on oral anticoagulant died because of digestive bleeding. The five patients who were on aspirin and died of cerebral hemorrhage were all uncontrolled hypertensive patients. Our results suggest that antiplatelet therapy represent a high risk for cerebral hemorrhage in patients with end-stage renal disease on chronic hemodialysis especially in those with uncontrolled hypertension. In summary we conclude that prophylactic aspirin should be used with caution in hypertensive patients on HD
Mabel Aoun has graduated in 2004 as a Nephrologist from the Universit? Saint-Joseph in Beirut-Lebanon. She completed her fellowship in nephrology at Kremlin- Bic?tre Hospital in Paris-France. She has a diploma in Renal Pathology from Universit? Saint-Antoine, Paris. She is the head of department of Nephrology and Dialysis at Saint-Georges Hospital Ajaltoun-Lebanon. She was responsible for the training of interns and residents from Saint-Joseph University and Kaslik University between 2007-2012. She is also a consultant in nephrology at the lebanese ministry of public health since 2012. Her main interests are glomerulonephritis? pathology and treatment as well as the improvement of haemodialysis and peritoneal dialysis treatments in her country
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version